Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.
The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.
Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.
Price: 108.87, Change: -0.10, Percent Change: -0.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.